ATE437175T1 - Infektiöse cdna eines zugelassenen impfstammes des masern virus. verwendung in immunogenen zusammensetzungen - Google Patents

Infektiöse cdna eines zugelassenen impfstammes des masern virus. verwendung in immunogenen zusammensetzungen

Info

Publication number
ATE437175T1
ATE437175T1 AT02291551T AT02291551T ATE437175T1 AT E437175 T1 ATE437175 T1 AT E437175T1 AT 02291551 T AT02291551 T AT 02291551T AT 02291551 T AT02291551 T AT 02291551T AT E437175 T1 ATE437175 T1 AT E437175T1
Authority
AT
Austria
Prior art keywords
immunogenic compositions
measles virus
vaccine strain
approved vaccine
infectious cdna
Prior art date
Application number
AT02291551T
Other languages
English (en)
Inventor
Frederic Tangy
Chantal Combredet
Valerie Labrousse-Najburg
Michel Brahic
Original Assignee
Pasteur Institut
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29716946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE437175(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pasteur Institut, Centre Nat Rech Scient filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE437175T1 publication Critical patent/ATE437175T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/12—Mumps virus; Measles virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18441—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10241—Use of virus, viral particle or viral elements as a vector
    • C12N2795/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT02291551T 2002-06-20 2002-06-20 Infektiöse cdna eines zugelassenen impfstammes des masern virus. verwendung in immunogenen zusammensetzungen ATE437175T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02291551A EP1375512B1 (de) 2002-06-20 2002-06-20 Infektiöse cDNA eines zugelassenen Impfstammes des Masern Virus. Verwendung in immunogenen Zusammensetzungen

Publications (1)

Publication Number Publication Date
ATE437175T1 true ATE437175T1 (de) 2009-08-15

Family

ID=29716946

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02291551T ATE437175T1 (de) 2002-06-20 2002-06-20 Infektiöse cdna eines zugelassenen impfstammes des masern virus. verwendung in immunogenen zusammensetzungen

Country Status (14)

Country Link
US (3) US9005961B2 (de)
EP (5) EP1375512B1 (de)
KR (1) KR101227128B1 (de)
CN (1) CN100577683C (de)
AT (1) ATE437175T1 (de)
AU (1) AU2003266950A1 (de)
BR (1) BRPI0312173B8 (de)
CA (1) CA2489052C (de)
CY (1) CY1109506T1 (de)
DE (1) DE60233038D1 (de)
DK (2) DK1375512T3 (de)
ES (2) ES2330309T3 (de)
PT (1) PT1375512E (de)
WO (1) WO2004000876A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201750A1 (de) * 2000-10-26 2002-05-02 Genopoietic Synthetische Viren und ihre Verwendungen
EP1375512B1 (de) * 2002-06-20 2009-07-22 Institut Pasteur Infektiöse cDNA eines zugelassenen Impfstammes des Masern Virus. Verwendung in immunogenen Zusammensetzungen
ES2427139T3 (es) * 2002-06-20 2013-10-29 Institut Pasteur Virus recombinantes del sarampión que expresan epítopos de antígenos de virus de ARN y uso de los virus recombinantes para la preparación de composiciones de vacuna
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
US20090004203A1 (en) * 2007-05-29 2009-01-01 Vical Incorporated Methods of treating measles infectious disease in mammals
KR101718497B1 (ko) * 2007-11-26 2017-03-22 런던 스쿨 오브 하이진 앤 트로피컬 메디신 레오바이러스과 바이러스의 백신용 바이러스 균주를 제조하는 방법
EP2085479A1 (de) * 2008-01-31 2009-08-05 Institut Pasteur Reverse Genetik von Negativstrang-RNA-Viren in Hefe
EP2420242A1 (de) 2010-08-20 2012-02-22 Lauer, Ulrich M. Onkolytisches Masernvirus
WO2013074501A1 (en) 2011-11-14 2013-05-23 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
EP2712871A1 (de) 2012-09-27 2014-04-02 Institut Pasteur Rekombinantes Masernvirus zur Expression von Chikungunya-Virus-Polypeptiden und deren Anwendungen
EP2759301A1 (de) 2013-01-24 2014-07-30 Institut Pasteur Verwendung eines genetisch modifizierten infektiösen Masernvirus mit erhöhten pro-apoptotischen Eigenschaften (MVDeltaC-Virus)
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
EP2959915A1 (de) 2014-06-23 2015-12-30 Institut Pasteur Chimäres Dengue-Virus-Polyepitop aus Fragmenten nichtstruktureller Proteine und deren Verbindung in einer immunogenen Zusammensetzung gegen Dengue-Virus-Infektion
EP3103474A1 (de) * 2015-06-12 2016-12-14 Institut Pasteur Lebendes rekombinantes masern-m2-virus und dessen verwendung bei auslösung von immunität gegen influenzaviren
EP3184119A1 (de) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatografiebasierte reinigungsstrategien für viren auf basis eines maserngerüsts
JP6949468B2 (ja) * 2016-10-17 2021-10-13 ルプレヒト−カールス−ウニベルジテート ハイデルベルク 腫瘍抗原をコードする麻疹ウイルス
EP3622078A1 (de) * 2017-05-09 2020-03-18 Invectys Rekombinanter masernimpfstoff mit htert-expression
EP3412307A1 (de) 2017-06-07 2018-12-12 Institut Pasteur Zika-virus-proteine zur expression eines rekombinanten masernvirus und deren anwendungen
MX2020004833A (es) 2017-11-09 2021-01-08 Pasteur Institut Un poliepitopo quimerico del virus del zika que comprende proteinas no estructurales y su uso en una composicion inmunogenica.
US11976305B2 (en) * 2017-12-21 2024-05-07 Institut Pasteur Lassa vaccine
CN111218475A (zh) * 2018-11-23 2020-06-02 成都生物制品研究所有限责任公司 一种拯救麻疹Schwarz/Moraten疫苗株的系统和方法
EP3865180A1 (de) * 2020-02-13 2021-08-18 Institut Pasteur Lebende rekombinante masernviren, die coronavirus-antigene exprimieren, verwendung davon zur erzeugung von immunität gegen coronaviren
AU2021218985A1 (en) * 2020-02-13 2022-08-25 Institut Pasteur Measles-vectored COVID-19 immunogenic compositions and vaccines
EP3936517A1 (de) 2020-07-08 2022-01-12 Institut Pasteur Verbesserter masernvirusimpfstoffvektor basierend auf mehreren zusätzlichen tandemtranskriptionseinheiten
US20240093233A1 (en) 2021-01-13 2024-03-21 Viroxis Measles-hiv or measles-htlv vaccine
CN113293148B (zh) * 2021-03-10 2022-10-25 上海青赛生物科技有限公司 一种h基因替换的嵌合麻疹减毒株的构建
WO2022195900A1 (ja) * 2021-03-15 2022-09-22 国立大学法人東京大学 組換え麻疹ウイルス
WO2026013289A1 (en) 2024-07-12 2026-01-15 Institut Pasteur Measles-mumps-rubella (mmr) vaccines

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7007491A (en) 1990-02-02 1991-08-08 Schweiz. Serum- & Impfinstitut Bern Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
JP3045581B2 (ja) 1991-10-14 2000-05-29 社団法人北里研究所 麻疹ワクチンウイルス株同定方法
EP0780475B2 (de) * 1995-08-09 2006-07-19 SCHWEIZ. SERUM- & IMPFINSTITUT BERN Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
WO1998013501A2 (en) * 1996-09-27 1998-04-02 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales
ES2345614T3 (es) 1997-02-28 2010-09-28 Sanofi Pasteur Biologics Co. Vacunas quimericas de flavivirus.
BRPI9701774B8 (pt) * 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
US6410023B1 (en) * 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
IL138681A0 (en) * 1998-03-26 2001-10-31 American Cyanamid Co Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b
EP1995310B1 (de) * 1998-06-03 2013-04-24 Wyeth Holdings Corporation Neuartige Verfahren zur Rettung von RNA-Viren
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
BR0012938A (pt) * 1999-08-02 2003-04-29 American Home Prod Método para a produzir um vìrus recombinante de caxumba, vìrus recombinante de caxumba, composição, método para imunizar um indivìduo, molécula de ácido nucleico, plasmìdeo, célula hospedeira, composição farmacêutica, e sequência de nucleotìdeos
AU5921101A (en) * 2000-04-28 2001-11-12 St Jude Childrens Res Hospital Dna transfection system for the generation of infectious influenza virus
ES2427139T3 (es) * 2002-06-20 2013-10-29 Institut Pasteur Virus recombinantes del sarampión que expresan epítopos de antígenos de virus de ARN y uso de los virus recombinantes para la preparación de composiciones de vacuna
EP1375512B1 (de) * 2002-06-20 2009-07-22 Institut Pasteur Infektiöse cDNA eines zugelassenen Impfstammes des Masern Virus. Verwendung in immunogenen Zusammensetzungen
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
CA2508266A1 (fr) 2005-06-20 2006-12-20 Institut Pasteur Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae
DK1939214T3 (da) 2006-12-22 2013-10-14 Pasteur Institut Celler og metodik til at generere ikke-segmenterede negativstrengede RNA-vira
BRPI0909547A2 (pt) * 2008-05-26 2019-03-06 Cadila Healthcare Ltd. vacina combinada de sarampo - hpv, vetor e hospedero
KR20120014918A (ko) * 2009-05-05 2012-02-20 카딜라 핼쓰캐어 리미티드 홍역-말라리아 조합 백신

Also Published As

Publication number Publication date
ES2663224T3 (es) 2018-04-11
DK1375512T3 (da) 2009-10-26
CA2489052A1 (en) 2003-12-31
PT1375512E (pt) 2009-09-23
CA2489052C (en) 2014-07-29
US20050227224A1 (en) 2005-10-13
CY1109506T1 (el) 2014-08-13
AU2003266950A1 (en) 2004-01-06
US9701944B2 (en) 2017-07-11
BRPI0312173B8 (pt) 2021-05-25
EP1375512A1 (de) 2004-01-02
EP2311853A1 (de) 2011-04-20
EP1375512B1 (de) 2009-07-22
US9005961B2 (en) 2015-04-14
WO2004000876A8 (en) 2005-03-03
BR0312173A (pt) 2005-04-05
DE60233038D1 (de) 2009-09-03
BRPI0312173B1 (pt) 2019-05-07
DK2311853T3 (en) 2018-04-16
CN100577683C (zh) 2010-01-06
US20130296541A1 (en) 2013-11-07
HK1061568A1 (en) 2004-09-24
US20150275184A1 (en) 2015-10-01
CN1662553A (zh) 2005-08-31
KR20050058288A (ko) 2005-06-16
EP1513872A1 (de) 2005-03-16
EP2311853B1 (de) 2017-12-27
WO2004000876A1 (en) 2003-12-31
ES2330309T3 (es) 2009-12-09
EP2065393A1 (de) 2009-06-03
AU2003266950A8 (en) 2004-01-06
EP2110382A1 (de) 2009-10-21
KR101227128B1 (ko) 2013-01-29
US9005925B2 (en) 2015-04-14

Similar Documents

Publication Publication Date Title
DE60233038D1 (de) Infektiöse cDNA eines zugelassenen Impfstammes des Masern Virus. Verwendung in immunogenen Zusammensetzungen
EA200501890A1 (ru) Вирусы гриппа высокого титра для приготовления вакцин и генной терапии
NL300897I2 (nl) Neisseira meningitidis serogroep B recombinant gelipideerd fHbp subfamilie A05 eiwit
DK1185691T3 (da) Genomiske neisseriasekvenser og fremgangmåder til anvendelse deraf
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
MA30581B1 (fr) Vaccin viral recombinant
ATE419369T1 (de) Chimäre mensch-rinder respiratory syncytial virus vakzinen
MXPA05011110A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.
CY1112749T1 (el) Εμβολια διεγερσης/αναμνησης κατα της ελονοσιας
DK1660528T3 (da) Mutein af tåre-lipocalin
PT1487485E (pt) Adjuvantes de imidazoquinolina para vacinas de adn
WO2007002008A3 (en) Methods and compositions for expressing negative-sense viral rna in canine cells
EA200600403A1 (ru) Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки
NO20082149L (no) Hundeinfluensavirus og relaterte sammensetninger og fremgangsmater for bruk
JP2014507146A5 (de)
DK1409692T3 (da) Nye peptider afledt af G-proteinet fra RSV, og anvendelse heraf i en vaccine
EP1315816A4 (de) Genmanipulierte dna-vakzine zur co-expression, methoden zu deren herstellung und deren verwendungen(18.03.02)
EA200601043A1 (ru) Промоторы для экспрессии в модифицированном вирусе осповакцины штамма анкара
EP1989316A4 (de) Verfahren zur herstellung von rekombinantem virus, dna-konstrukte, rekombinantes virus und impfstoffzusammensetzungen
ATE469170T1 (de) Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
WO2005011571A3 (en) Hepatitis virus core proteins as vaccine platforms and methods of use thereof
ATE420658T1 (de) Imidazoquinolinamine als adjuvantien für hiv dna vakzine
DE60040219D1 (de) Infektiöses cdna klon des gb-virus b und dessen verwendungen
ATE505482T1 (de) Impfstoff gegen infektiöses lachsanämievirus
FR2829498B1 (fr) Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1375512

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1375512

Country of ref document: EP